Vensana Capital Closes $425 Million Fund III

Gunderson Dettmer represented client Vensana Capital in closing $425 million in capital commitments for its latest fund, Vensana Capital III.

Vensana Capital is a venture capital and growth equity investment firm dedicated to partnering with innovative medical technology companies in their development and commercial stages. The firm invests across all areas of medtech, with a particular focus on medical device and data science-oriented companies that have the potential to create new clinical standards of care while also helping to make healthcare more efficient, accessible and cost-effective.

In the announcement of the fund formation, Vensana Capital Managing Partner Kirk Nielsen said, “We are incredibly proud of the progress Vensana has made since launch as we work tirelessly to build the leading medtech investment and company building platform, and we are beyond grateful for the continued strong support of our limited partners.”  Vensana Capital Managing Partner Justin Klein added, “Our entire team is excited about the opportunity ahead as we continue to partner with entrepreneurs who are transforming healthcare with breakthrough innovations in medical technology.”

The Gunderson Dettmer deal team was led by Tyler Kirtley and Nick Guttilla and included David Myerson and Bria Guitano.

Companies
Vensana